glp-1 canada weight loss Agonists: The New Era of and Diabetes Care 3 million Canadians use GLP-1

Clinical Implications of ALA ALA has been used in clinical practice for 70 years to alleviate symptoms associated with various diseases, including neurodegenerative disorders, diabetes, cancer, age-related cardiovascular issues, neuromuscular conditions, weight gain caused by antipsychotic medications, and metabolic obesity [1,8,15]

The effects appear to rely on GLP-1Rs located in the NAc shell and lateral septum, supporting the notion of region-specific neuromodulation

This dosing flexibility is an important consideration in the Mounjaro vs Trulicity decision

Clinical trials have shown that patients using Mounjaro can lose up to 22.5% of their body weight, compared to about 15% with Ozempic at maximum doses

Tailored Treatment Plans: Every treatment is customized to your specific aesthetic needs and wellness goals

Stienstra, R